| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nearly one in five American workers tested positive for drug use in long-term screenings last year, driven by a rise in cannabis consumption that is forcing companies to reevaluate their hiring practices. According to new data from Quest Diagnostics, 19.1 percent of workers screened via hair analysis in 2025 returned a positive result, representing a 46 percent increase from 2021. Marijuana accounted for 52.5 percent of those positive hair tests.
Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets administrative friction from multi-biomarker orders and dense reports by reducing ordering steps, accelerating account setup, and returning more usable results inside routine EHR workflows.
The Quest Diagnostics Foundation said this week that it has awarded nearly $5 million in grant funding to four Miami-area non-profits to improve chronic and maternal health outcomes. With the funding, which was granted to the Florida International University Foundation, Urban Health Partnerships, The Health Council of South, and US Hunger, the Quest Diagnostics Foundation aims to expand healthcare access in the area, including through no-cost lab testing.
Quest Diagnostics said Wednesday that its Haystack MRD test has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for use in identifying residual or recurring disease in patients with a range of solid tumors. With the approval, Haystack MRD is now available for patient testing in all 50 states and the District of Columbia. Quest launched the circulating tumor DNA liquid biopsy test in late 2024.
A hard-to-kill species of pneumonia-causing bacteria that has traditionally been found mainly in hospitals is now spreading in U.S. community settings, according to research that could help lead to new treatments. To learn more about its patterns of spread, researchers analyzed multidrug-resistant Klebsiella pneumoniae detected in urine and blood samples from more than 2,000 people in 42 states at local offices of Quest Diagnostics, a leading provider of outpatient laboratory testing.